Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03819465
Recruitment Status : Active, not recruiting
First Posted : January 28, 2019
Last Update Posted : June 30, 2022
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Condition or disease Intervention/treatment Phase
Metastatic Non-Small Cell Lung Cancer (NSCLC) Drug: Durvalumab Drug: Danvatirsen Drug: Oleclumab Drug: MEDI5752 Drug: Pemetrexed Drug: Carboplatin Drug: Gemcitabine Drug: Cisplatin Drug: Nab-paclitaxel Drug: AZD2936 Phase 1

Detailed Description:
This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC).
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 258 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Treatment arms for MEDI5752 (Arms A4 and B4) will enroll 42 and 60 patients, respectively. Arm B5 (AZD2936+chemotherapy) will enroll 60 patients.

For all other treatment arms, 30 patients will be enrolled into each arm; additional patients may be enrolled in order to have 30 evaluable patients per arm (ie, dosed).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)
Actual Study Start Date : December 27, 2018
Estimated Primary Completion Date : March 26, 2026
Estimated Study Completion Date : March 26, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
Drug Information available for: Durvalumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: A1
Durvalumab
 Drug: Durvalumab
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI4736
Experimental: A2
Durvalumab + danvatirsen
 Drug: Durvalumab
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI4736

Drug: Danvatirsen
Danvatirsen IV Loading dose C1D1, C1D3, and C1D5 then once a week (q1w) starting at C1D8
Other Name: AZD9150
Experimental: A3
Durvalumab + oleclumab
 Drug: Durvalumab
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI4736

Drug: Oleclumab
Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at C3D1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI9447
Experimental: A4
MEDI5752
 Drug: MEDI5752
MEDI5752 IV Every 3 weeks (q3w)
Experimental: B1
Durvalumab + Investigator's choice of chemotherapy
 Drug: Durvalumab
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI4736

Drug: Pemetrexed
Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either q3w or q4w (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study

Drug: Carboplatin
Carboplatin IV Day 1 of each 21-day cycle

Drug: Gemcitabine
Gemcitabine IV Days 1 and 8 of each 21-day cycle

Drug: Cisplatin
Cisplatin IV Day 1 of each 21-day cycle

Drug: Nab-paclitaxel
Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
Experimental: B2
Durvalumab + Investigator's choice of chemotherapy + danvatirsen
 Drug: Durvalumab
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI4736

Drug: Danvatirsen
Danvatirsen IV Loading dose C1D1, C1D3, and C1D5 then once a week (q1w) starting at C1D8
Other Name: AZD9150

Drug: Pemetrexed
Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either q3w or q4w (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study

Drug: Carboplatin
Carboplatin IV Day 1 of each 21-day cycle

Drug: Gemcitabine
Gemcitabine IV Days 1 and 8 of each 21-day cycle

Drug: Cisplatin
Cisplatin IV Day 1 of each 21-day cycle

Drug: Nab-paclitaxel
Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
Experimental: B3
Durvalumab + investigator's choice of chemotherapy + oleclumab
 Drug: Durvalumab
Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI4736

Drug: Oleclumab
Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) starting at C3D1 Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w) starting at C5D1
Other Name: MEDI9447

Drug: Pemetrexed
Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either q3w or q4w (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study

Drug: Carboplatin
Carboplatin IV Day 1 of each 21-day cycle

Drug: Gemcitabine
Gemcitabine IV Days 1 and 8 of each 21-day cycle

Drug: Cisplatin
Cisplatin IV Day 1 of each 21-day cycle

Drug: Nab-paclitaxel
Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
Experimental: B4
MEDI5752
 Drug: MEDI5752
MEDI5752 IV Every 3 weeks (q3w)
Experimental: A5
AZD2936
 Drug: AZD2936
AZD2936 IV
Experimental: B5
AZD2936 + chemotherapy
 Drug: Pemetrexed
Pemetrexed IV Day 1 of each 21-day cycle Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either q3w or q4w (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter Arm B5: Day 1 of each 21-day cycle throughout the study

Drug: Carboplatin
Carboplatin IV Day 1 of each 21-day cycle

Drug: Cisplatin
Cisplatin IV Day 1 of each 21-day cycle

Drug: AZD2936
AZD2936 IV


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Assessment of AEs by CTCAE v5.0 [ Time Frame: From informed consent until the safety follow-up visit 3 months after the last dose of study drug ]
    Assessment of safety and tolerability of each treatment arm


Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: Approximately 24 months ]
    Assessment of the efficacy of each treatment arm according to RECIST 1.1. ORR: The percentage of evaluable patients with a confirmed Investigator-assessed visit response of CR or PR

  2. Duration of Response (DoR) [ Time Frame: Tumor assessments occur every 6-9 weeks until week 48-54 & then every 12 or 18 weeks, depending on treatment arm until confirmed radiological progression, death, withdrawal of consent or study completion, up to approximately 24 months ]
    Assessment of the efficacy of each treatment arm according to RECIST 1.1. DoR: Time from date of first detection of objective response until the date of objective radiological disease progression

  3. Progression Free Survival (PFS) [ Time Frame: Tumor assessments occur every 6-9 weeks until week 48-54 & then every 12/18 weeks based on treatment arm until progression, death, withdrawal or study completion up to 24 months. Further PFS data will be collected until 6 months post-last patient dosed ]
    Assessment of the efficacy of each treatment arm according to RECIST 1.1. PFS: Time from date of treatment assignment until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression)

  4. Overall Survival (OS) [ Time Frame: Approximately 42 months. Additional OS data will be collected until approximately 6 months post-last patient dosed ]
    OS: Time from date of treatment assignment until the date of death by any cause

  5. Blood concentration of durvalumab and novel oncology therapies [ Time Frame: From Cycle 1 Day 1 until Cycle 6 or 7 Day 1 (each cycle is 21 or 28 days) depending on treatment arm, then every 3 cycles (except for arms A5 & B5), at end of treatment (Arms A4 & B4, A5 & B5 only), and until 3 months following treatment discontinuation ]
    Drug concentration of durvalumab and novel oncology therapies

  6. Frequency of anti-drug antibodies (ADAs) for durvalumab and applicable novel oncology therapies [ Time Frame: From Cycle 1 Day 1 until Cycle 6 or 7 Day 1 (21- or 28-day cycles) depending on treatment arm, then every 3 or 6 cycles (except for arms A5&B5), at end of treatment (arms A4&B4, A5&B5 only), until 3 or 6 months following treatment discontinuation ]
    Investigation of the immunogenicity of durvalumab and each applicable novel oncology therapy in all applicable treatment arms


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
  • No prior chemotherapy or any other systemic therapy for metastatic NSCLC
  • Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred >12 months from end of last therapy
  • Known tumor PD-L1 status
  • Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care
  • WHO/ECOG status at 0 or 1 at enrollment
  • Life expectancy of at least 12 weeks
  • Troponin I or T ≤ ULN (per institutional guidelines)

Exclusion Criteria:

  • Active or prior documented autoimmune or inflammatory disorders
  • History of active primary immunodeficiency
  • Any prior chemotherapy or any other systemic therapy for metastatic NSCLC
  • Untreated CNS metastases
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03819465


Locations
Layout table for location information
United States, Iowa
Research Site
Iowa City, Iowa, United States, 52242
United States, Pennsylvania
Research Site
Pittsburgh, Pennsylvania, United States, 15212
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 37203
Austria
Research Site
Salzburg, Austria, 5020
Research Site
Wien, Austria, 1140
Belgium
Research Site
Edegem, Belgium, 2650
Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada
Research Site
Toronto, Canada, M5G 2M9
Korea, Republic of
Research Site
Seoul, Korea, Republic of, 03080
Research Site
Seoul, Korea, Republic of, 03722
Research Site
Seoul, Korea, Republic of, 05505
Research Site
Seoul, Korea, Republic of, 06351
Poland
Research Site
Bialystok, Poland, 15-027
Research Site
Bydgoszcz, Poland, 85-796
Research Site
Gdańsk, Poland, 80-214
Research Site
Grudziądz, Poland, 86-300
Research Site
Olsztyn, Poland, 10-357
Research Site
Tomaszów Mazowiecki, Poland, 97-200
Research Site
Warszawa, Poland, 02-781
Research Site
Wroclaw, Poland, 53-413
Russian Federation
Research Site
Krasnoyarsk, Russian Federation, 660133
Research Site
Moscow, Russian Federation, 115478
Research Site
Saint Petersburg, Russian Federation, 197758
Research Site
Sankt-Peterburg, Russian Federation, 197758
Research Site
St.Petersburg, Russian Federation, 191014
Spain
Research Site
Barcelona, Spain, 08025
Research Site
Barcelona, Spain, 08035
Research Site
Barcelona, Spain, 8003
Research Site
Madrid, Spain, 28034
Research Site
Madrid, Spain, 28041
Research Site
Sevilla, Spain, 41013
Taiwan
Research Site
Kaohsiung, Taiwan, 807
Research Site
Taichung City, Taiwan, 402
Research Site
Taichung, Taiwan, 40705
Research Site
Tainan City, Taiwan, 70403
Research Site
Taipei, Taiwan, 10002
Research Site
Taipei, Taiwan, 112
Research Site
Taipei, Taiwan, 235
Research Site
Taoyuan, Taiwan, 333
Thailand
Research Site
Bangkok, Thailand, 10330
Research Site
Bangkok, Thailand, 10700
Research Site
Chiang Mai, Thailand, 50200
Research Site
Hat Yai, Thailand, 90110
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Sandip Patel, MD UCSD Morres Cancer Center
Principal Investigator: Chih-Hsin Yang, MD National Taiwan University Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03819465    
Other Study ID Numbers: D933IC00001
2018-001748-74 ( EudraCT Number )
First Posted: January 28, 2019    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
URL: https://astrazenecagroup-dt.pharmacm.com/DT/Home

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
First-Line Stage IV Metastatic Non-Small Cell Lung Cancer
Stage IV Metastatic Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
 Non-Small Cell Lung
Non-Small Cell
NSCLC
Non-Small Cell Lung Carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Gemcitabine
Paclitaxel
Carboplatin
Pemetrexed
Durvalumab
 Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Folic Acid Antagonists